Published :
Tables : 46
Figures : 43
Category : Healthcare
No. of Pages : 216
Report Code : HC-U2865
Pain Management Drugs Market is forecasted to value over CAGR of 3.5% from the forecast period 2022-2028. FutureWise Market Research has instantiated a report that provides an intricate analysis of Pain Management Drugs Market trends that shall affect the overall market growth. Furthermore, it includes detailed information on the graph of profitability, market share and regional proliferation of this business. Moreover, the report offers insights on the current stature of prominent market players in the competitive landscape analysis of the market. According to the research study conducted by FutureWise research analysts, the Pain Management Drugs Market is anticipated to attain substantial growth by the end of the forecast period. The report explains that this business is predicted to register a noteworthy growth rate over the forecast period. This report provides crucial information pertaining to the total valuation that is presently held by this industry and it also lists the segmentation of the Pain Management Drugs Market along with the growth opportunities present across this business vertical. Major players included in the Pain Management Drugs Market are: • Novartis AG • Eli Lilly & Company • Abbott Laboratories • Endo Health Solutions, Inc. • Purdue Pharma L.P. • Pfizer, Inc. • F. Hoffmann La Roche Ltd. • Merck & Co. Inc. • Johnson & Johnson • GlaxoSmithKline Plc. • Mylan NV • Allergen Inc • Bayer AG • Bristol-Myers Squibb • Valeant Pharmaceuticals International Inc • Boehringer Ingelheim • Sorrento Therapeutics • WEX Pharmaceuticals • Zynerba Pharmaceuticals (Note: The list of the major players will be updated with the latest market scenario and trends) Pain Management Drugs Market Segmentation: By Drug Class • NSAIDs • Anesthetics • Anticonvulsants • Antimigraine Agents • Antidepressants • Opioids o Tramadol o Hydrocodone o Oxycodone o Others • Nonnarcotic Analgesics By Indication • Arthritic Pain • Neuropathic Pain • Cancer Pain • Chronic Back Pain • Postoperative Pain • Migraine • Fibromyalgia • Muscle sprain/strain • Bone fracture • Acute appendicitis • Others By Pain Type • Chronic pain • Acute pain By Region • North America • Europe • Asia-Pacific • Latin America • Middle East and Africa Competitive Landscape: • Tier 1 players- established companies in the market with a major market share • Tier 2 players • Emerging players which are growing rapidly • New Entrants FutureWise Key Takeaways: • Growth prospects • SWOT analysis • Key trends • Key data-points affecting market growth Objectives of the Study: • To provide with an exhaustive analysis on the Pain Management Drugs Market by drug class, by indication, by pain type and by region • To cater comprehensive information on factors impacting market growth (drivers, restraints, opportunities, and industry-specific restraints) • To evaluate and forecast micro-markets and the overall market • To predict the market size, in key regions— North America, Europe, Asia Pacific, Latin America and Middle East and Africa • To record and evaluate competitive landscape mapping- product launches, technological advancements, mergers and expansions Flexible Delivery Model: • We have a flexible delivery model and you can suggest changes in the scope/table of content as per your requirement • The customization services offered are free of charge with purchase of any license of the report. • You can directly share your requirements/changes to the current table of content to: sales@futurewiseresearch.com
FutureWise Market Research has instantiated a report that provides an intricate analysis of Pain Management Drugs Market trends that shall affect the overall market growth. Furthermore, it includes detailed information on the graph of profitability, market share and regional proliferation of this business. Moreover, the report offers insights on the current stature of prominent market players in the competitive landscape analysis of the market. According to the research study conducted by FutureWise research analysts, the Pain Management Drugs Market is anticipated to attain substantial growth by the end of the forecast period. The report explains that this business is predicted to register a noteworthy growth rate over the forecast period. This report provides crucial information pertaining to the total valuation that is presently held by this industry and it also lists the segmentation of the Pain Management Drugs Market along with the growth opportunities present across this business vertical.
Major players included in the Pain Management Drugs Market are: • Novartis AG • Eli Lilly & Company • Abbott Laboratories • Endo Health Solutions, Inc. • Purdue Pharma L.P. • Pfizer, Inc. • F. Hoffmann La Roche Ltd. • Merck & Co. Inc. • Johnson & Johnson • GlaxoSmithKline Plc. • Mylan NV • Allergen Inc • Bayer AG • Bristol-Myers Squibb • Valeant Pharmaceuticals International Inc • Boehringer Ingelheim • Sorrento Therapeutics • WEX Pharmaceuticals • Zynerba Pharmaceuticals
(Note: The list of the major players will be updated with the latest market scenario and trends) Pain Management Drugs Market Segmentation:
By Drug Class • NSAIDs • Anesthetics • Anticonvulsants • Antimigraine Agents • Antidepressants • Opioids o Tramadol o Hydrocodone o Oxycodone o Others • Nonnarcotic Analgesics By Indication • Arthritic Pain • Neuropathic Pain • Cancer Pain • Chronic Back Pain • Postoperative Pain • Migraine • Fibromyalgia • Muscle sprain/strain • Bone fracture • Acute appendicitis • Others By Pain Type • Chronic pain • Acute pain By Region • North America • Europe • Asia-Pacific • Latin America • Middle East and Africa
Competitive Landscape: • Tier 1 players- established companies in the market with a major market share • Tier 2 players • Emerging players which are growing rapidly • New Entrants
FutureWise Key Takeaways: • Growth prospects • SWOT analysis • Key trends • Key data-points affecting market growth
Objectives of the Study: • To provide with an exhaustive analysis on the Pain Management Drugs Market by drug class, by indication, by pain type and by region • To cater comprehensive information on factors impacting market growth (drivers, restraints, opportunities, and industry-specific restraints) • To evaluate and forecast micro-markets and the overall market • To predict the market size, in key regions— North America, Europe, Asia Pacific, Latin America and Middle East and Africa • To record and evaluate competitive landscape mapping- product launches, technological advancements, mergers and expansions
Flexible Delivery Model: • We have a flexible delivery model and you can suggest changes in the scope/table of content as per your requirement • The customization services offered are free of charge with purchase of any license of the report. • You can directly share your requirements/changes to the current table of content to: sales@futurewiseresearch.com
1. Market Introduction 1.1. Objectives of the Study 1.2. Market Definition 1.3. Market Scope 1.3.1. Years Considered for the Study 1.3.2. Market Covered 1.4. Currency 1.5. Limitations 1.6. Stakeholders 2. Research Methodology 2.1. Research Data 2.1.1. Secondary Data 2.1.1.1. Key Data from Secondary Sources 2.1.2. Primary Data 2.1.2.1. Key Data from Primary Sources 2.2. Market Size Estimation 2.3. Market Breakdown and Data Triangulation 2.4. Assumptions for the Study 3. Executive Summary 3.1. Market Outlook 3.2. Segment Outlook 3.3. Competitive Insights 4. Global Pain Management Drugs Market Variables, Trends & Scope 4.1. Market Lineage Outlook 4.2. Penetration and Growth Prospect Mapping 4.3. Industry Value Chain Analysis 4.4. Cost Analysis Breakdown 4.5. Technology Overview 4.6. Regulatory Framework 4.6.1. Reimbursement Framework 4.6.2. Standards and Compliances 5. Global Pain Management Drugs Market Overview 5.1. Market Dynamics 5.1.1. Market Driver Analysis 5.1.1.1. Increasing focus of Pain Management Drugs Companies on Brand Protection 5.1.1.2. Untapped Opportunities in Emerging Regions 5.1.2. Market Restraint Analysis 5.1.2.1. High Cost Associated with Implementation of Predictive Analysis 5.1.3. Industry Challenges 5.1.3.1. Presence of Ambiguous Regulatory Framework 6. Global Pain Management Drugs Market Analysis Tools 6.1. Industry Analysis - Porter’s 6.1.1. Supplier Power 6.1.2. Buyer Power 6.1.3. Substitution Threat 6.1.4. Threat from New Entrants 6.1.5. Competitive Rivalry 6.2. Pestel Analysis 6.2.1. Political Landscape 6.2.2. Environmental Landscape 6.2.3. Social Landscape 6.2.4. Technology Landscape 6.2.5. Legal Landscape 6.3. Major Deals And Strategic Alliances Analysis 6.3.1. Joint Ventures 6.3.2. Mergers and Acquisitions 6.3.3. Licensing and Partnership 6.3.4. Technology Collaborations 6.3.5. Strategic Divestments 6.4. Market Entry Strategies 6.5. Case Studies 7. Global Pain Management Drugs Market, By Drug Class Historical Analysis and Forecast 2022-2028 (USD Million) 7.1. NSAIDs 7.2. Anesthetics 7.3. Anticonvulsants 7.4. Antimigraine Agents 7.5. Antidepressants 7.6. Opioids 7.6.1. Tramadol 7.6.2. Hydrocodone 7.6.3. Oxycodone 7.6.4. Others 7.7. Nonnarcotic Analgesics 8. Global Pain Management Drugs Market, By Indication Historical Analysis and Forecast 2022-2028 (USD Million) 8.1. Arthritic Pain 8.2. Neuropathic Pain 8.3. Cancer Pain 8.4. Chronic Back Pain 8.5. Postoperative Pain 8.6. Migraine 8.7. Fibromyalgia 8.8. Muscle sprain/strain 8.9. Bone fracture 8.10. Acute appendicitis 8.11. Others 9. Global Pain Management Drugs Market, By Pain Type Historical Analysis and Forecast 2022-2028 (USD Million) 9.1. Chronic pain 9.2. Acute pain 10. North America Market Analysis 2016–2020 and Forecast 2022–2028 (USD Million) 10.1. Introduction 10.2. Historical Market Size (USD Million) Analysis By Country, 2016-2020 10.2.1. U.S.A 10.2.2. Canada 10.2.3. Mexico 10.3. Market Size (USD Million) Forecast for North America 2022-2028 11. Latin America Market Analysis 2016–2020 and Forecast 2022–2028 (USD Million) 11.1. Introduction 11.2. Regional Market Trends 11.3. Historical Market Size (USD Million) Analysis By Country, 2016-2020 11.3.1. Brazil 11.3.2. Venezuela 11.3.3. Argentina 11.3.4. Rest of Latin America 11.4. Market Size (USD Million) Forecast for Latin America 2022-2028 12. Europe Market Analysis 2016–2020 and Forecast 2022–2028 (USD Million) 12.1. Introduction 12.2. Historical Market Size (USD Million) Analysis By Country, 2016-2020 12.2.1. Germany 12.2.2. U.K 12.2.3. France 12.2.4. Italy 12.2.5. Spain 12.2.6. Russia 12.2.7. Poland 12.2.8. Switzerland 12.2.9. Rest of Western Europe 12.3. Market Size (USD Million) Forecast for Europe 2022-2028 13. Asia Pacific Market Analysis 2016–2020 and Forecast 2022–2028 (USD Million) 13.1. Introduction 13.2. Historical Market Size (USD Million) Analysis By Country, 2016-2020 13.2.1. Japan 13.2.2. China 13.2.3. Singapore 13.2.4. India 13.2.5. Australia and New Zealand 13.2.6. ASEAN 13.2.7. South Korea 13.2.8. Taiwan 13.2.9. Rest of Asia Pacific 13.3. Market Size (USD Million) Forecast for Asia Pacific 2022-2028 14. Middle East and Africa Market Analysis 2016–2020 and Forecast 2022–2028 (USD Million) 14.1. Introduction 14.2. Historical Market Size (USD Million) Analysis By Country, 2016-2020 14.2.1. GCC 14.2.2. Israel 14.2.3. South Africa 14.2.4. Rest of MEA 14.3. Market Size (USD Million) Forecast for MEA 2022-2028 15. Market Share Analysis and Competitive Landscape 15.1. Global Landscape - Key Players, Revenue and Presence 15.2. Global Share Analysis - Key Players (Tier 1, Tier 2, Tier 3) 15.3. Global Emerging Companies 15.4. North America - Market Share Analysis and Key Regional Players 15.5. Europe - Market Share Analysis and Key Regional Players 15.6. Asia Pacific - Market Share Analysis and Key Regional Players 15.7. Global Key Player - Growth Matrix 16. Company Profiles (Competition Dashboard, Competitors Deep Dive, Product Connected Devices and Disease Indication Portfolio, Financial Layouts) 16.1. Novartis AG 16.1.1. Company Overview 16.1.2. Product Portfolio 16.1.3. SWOT Analysis 16.1.4. Financial Overview 16.1.5. Strategic Overview 16.2. Eli Lilly & Company 16.2.1. Company Overview 16.2.2. Product Portfolio 16.2.3. SWOT Analysis 16.2.4. Financial Overview 16.2.5. Strategic Overview 16.3. Abbott Laboratories 16.3.1. Company Overview 16.3.2. Product Portfolio 16.3.3. SWOT Analysis 16.3.4. Financial Overview 16.3.5. Strategic Overview 16.4. Endo Health Solutions, Inc. 16.4.1. Company Overview 16.4.2. Product Portfolio 16.4.3. SWOT Analysis 16.4.4. Financial Overview 16.4.5. Strategic Overview 16.5 Purdue Pharma L.P. 16.5.1. Company Overview 16.5.2. Product Portfolio 16.5.3. SWOT Analysis 16.5.4. Financial Overview 16.5.5. Strategic Overview 16.6 Pfizer, Inc. 16.6.1. Company Overview 16.6.2. Product Portfolio 16.6.3. SWOT Analysis 16.6.4. Financial Overview 16.6.5. Strategic Overview 16.7. F. Hoffmann La Roche Ltd. 16.7.1. Company Overview 16.7.2. Product Portfolio 16.7.3. SWOT Analysis 16.7.4. Financial Overview 16.7.5. Strategic Overview 16.8. Merck & Co. Inc. 16.8.1. Company Overview 16.8.2. Product Portfolio 16.8.3. SWOT Analysis 16.8.4. Financial Overview 16.8.5. Strategic Overview 16.9. Johnson & Johnson 16.9.1. Company Overview 16.9.2. Product Portfolio 16.9.3. SWOT Analysis 16.9.4. Financial Overview 16.9.5. Strategic Overview 16.10. GlaxoSmithKline Plc. 16.10.1. Company Overview 16.10.2. Product Portfolio 16.10.3. SWOT Analysis 16.10.4. Financial Overview 16.10.5. Strategic Overview 16.11. Mylan NV 16.11.1. Company Overview 16.11.2. Product Portfolio 16.11.3. SWOT Analysis 16.11.4. Financial Overview 16.11.5. Strategic Overview 16.12. Allergen Inc 16.12.1. Company Overview 16.12.2. Product Portfolio 16.12.3. SWOT Analysis 16.12.4. Financial Overview 16.12.5. Strategic Overview 16.13. Bayer AG 16.13.1. Company Overview 16.13.2. Product Portfolio 16.13.3. SWOT Analysis 16.13.4. Financial Overview 16.13.5. Strategic Overview 16.14. Bristol-Myers Squibb 16.14.1. Company Overview 16.14.2. Product Portfolio 16.14.3. SWOT Analysis 16.14.4. Financial Overview 16.14.5. Strategic Overview 16.15. Valeant Pharmaceuticals International Inc 16.15.1. Company Overview 16.15.2. Product Portfolio 16.15.3. SWOT Analysis 16.15.4. Financial Overview 16.15.5. Strategic Overview 16.16. Boehringer Ingelheim 16.16.1. Company Overview 16.16.2. Product Portfolio 16.16.3. SWOT Analysis 16.16.4. Financial Overview 16.16.5. Strategic Overview 16.17. Sorrento Therapeutics 16.17.1. Company Overview 16.17.2. Product Portfolio 16.17.3. SWOT Analysis 16.17.4. Financial Overview 16.17.5. Strategic Overview 16.18. WEX Pharmaceuticals 16.18.1. Company Overview 16.18.2. Product Portfolio 16.18.3. SWOT Analysis 16.18.4. Financial Overview 16.18.5. Strategic Overview 16.19. Zynerba Pharmaceuticals. 16.19.1. Company Overview 16.19.2. Product Portfolio 16.19.3. SWOT Analysis 16.19.4. Financial Overview 16.19.5. Strategic Overview 17. Pre and Post COVID-19 Impact 17.1. Positive influence on the healthcare industry 17.2. The financial disruption of the manufacturing sector 17.3. Impact of COVID-19 on emerging companies 17.4. Significant mandates in the healthcare regulations initiated by administrations 17.5. The overall economic slowdown of the developing and developed nations 18. FutureWise SME Key Takeaway Points for Client
UK : +44 141 628 9353 US : +1 347 709 4931
OR
Excel Dataset
Infographics
PDF Report
Market Overview
PowerPoint Presentation
Consumer Perception and Procurement
Competitive Analysis
What’s Next
Market Data Forecast
Risks and Opportunity Assessment
Market Trends and Dynamics